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Abstract
Introduction: The effects of selected drugs (see below) on the efficacy of (131I) radioiodine therapy were examined.
Material and methods: The study involved 200 hyperthyroid patients, treated with radioactive iodine. They were divided into five groups
(40 persons in each). In Group I — patients were administered 131I and thiamazole; in Group II they were given — 131I and lithium carbona-
te; in Group III they were given — 131I only (the assumed absorbed dose — 150–200 Gy, the same as in Groups I and II, for which Group III
was a control group); in Group IV they were given — 131I and prednisone; and in Group V they were given — 131I only (250–350 Gy, the
same as in Group IV, for which Group V was a control group). Therapeutic results were analyzed after six months based on clinical and
hormonal status. The evaluation also included effects of the initial hormonal status on the outcome of 131I therapy in Groups II and IV
(v. respective controls, i.e. Groups III and V); such analysis was not performed in Group I because all the patients in that group were
initially hyperthyroid.
Results: In 145 patients (72.5%) the therapy with 131I was effective. In 55 patients (27.5%) the therapy was ineffective. The application of
thiamazole during the peritherapeutic period in patients treated with 131I reduced the effectiveness of radioiodine, while lithium carbonate
had no effect on the therapy outcome. Prednisone increased the effectiveness of the therapy with 131I. Normalisation of the initial concen-
tration of TSH was advantageous for the 131I therapeutic outcome only when the assumed absorbed doses of 150–200 Gy were applied,
while being of no avail for doses above 250 Gy.
Conclusions: The present results indicate the necessity of careful analysis of administered drugs in hyperthyroid patients while qualifying
them to 131I therapy. The initial concentration of TSH has no effect on the efficacy of radioiodine therapy in cases where absorbed doses are
regarded to be ablative. (Pol J Endocrinol 2010; 61 (1): 56–61)
Key words: hyperthyroidism, radioactive iodine, antithyroid drugs, lithium carbonate, corticosteroids
Streszczenie
Wstęp: W pracy zbadano wpływ tiamazolu, węglanu litu i prednizonu na skuteczność leczenia jodem radioaktywnym pacjentów z nad-
czynnością tarczycy.
Materiał i metody: Do badań zakwalifikowano 200 chorych z nadczynnością tarczycy, leczonych jodem radioaktywnym. Pacjentów
podzielono na 5 grup (40 osób w każdej). W grupie I — poza 131I — chorzy dodatkowo otrzymywali tiamazol (preparat Thyrozol), w grupie II
— oprócz 131I — węglan litu. Do grupy III zaliczono chorych, którzy otrzymali wyłącznie leczenie 131I przy założonej dawce pochłoniętej
150–200 Gy, czyli takiej samej, jak w grupie I i II; grupa III stanowiła grupę kontrolną dla tych dwóch grup. W grupie IV chorzy otrzymy-
wali leczenie 131I oraz — w okresie okołoterapeutycznym — prednizon w dawce 1 mg/kg mc. W grupie V — chorzy otrzymali wyłącznie
leczenie 131I (założona dawka pochłonięta 250–300 Gy), tak samo jak w grupie IV; grupa V stanowiła kontrolę dla grupy IV. Wyniki
leczenia zanalizowano po sześciu miesiącach na podstawie badania klinicznego i hormonalnego. Do oceny włączono także wpływ począt-
kowego stanu hormonalnego na skuteczność terapii 131I w grupach II i IV (względem odpowiednich grup kontrolnych, tj. grupy III i V). Takiej
analizy nie przeprowadzono w grupie I, ponieważ wszyscy pacjenci w tej grupie mieli początkowo nadczynność tarczycy.
Wyniki: U 145 pacjentów (72,5%) terapia 131I była skuteczna. U 55 pacjentów (27,5%) terapia okazała się nieskuteczna. Zastosowanie
tiamazolu w okresie okołoterapeutycznym u pacjentów leczonych 131I zmniejszyło skuteczność radiojodu, podczas gdy leczenie węgla-
nem litu nie miało wpływu na wyniki terapii. Prednizon zwiększył skuteczność leczenia 131I. Normalizacja początkowego stężenia hormo-
nu tyreotropowego (TSH, thyroid stimulating hormone) wpływała korzystnie na wynik leczenia 131I tylko wtedy, gdy założona dawka po-
chłonięta wynosiła 150–200 Gy, podczas gdy dla dawek powyżej 250 Gy korzystnego wpływu nie stwierdzono.
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The treatment of hyperthyroidism in the course of Gra-
ves’ disease (GD) and toxic nodular goitre (TNG) by
means of radioactive iodine (131I) is a commonly reco-
gnized and widely used therapeutic procedure in pa-
tients with preserved iodine uptake capacity of the thy-
roid gland [1–3].
It is known, both from clinical practice and from
numerous scientific reports, that it is not always possi-
ble to apply radioiodine in hyperthyroidism treatment
as monotherapy [4–6].
Hyperthyroid patients manifesting enhanced symp-
toms of toxicosis undergo, as a rule, special preparation
before 131I administration, including the administration
of antithyroid drugs, e.g. thiamazole, in order to reduce
hormonal resources in the thyroid gland [7, 8].
Radioiodine (131I) treatment of patients with GD and
coexisting Graves’ orbitopathy (GO) introduces the risk
of increased symptoms of the latter disease. Therefore,
corticosteroids are administered as a prophylactic pro-
tection [9, 10].
Effective half-life (EHL) is a dosimetric parameter
affecting the outcome of 131I therapy in treatment of
hyperthyroid disease. In other words, the term EHL
denotes the period during which the activity of the iso-
tope applied to a patient for therapeutic purpose is ha-
lved. EHL for 131I is, on average, six days. In 10-15% of
patients, a short EHL is observed, which is then correc-
ted by lithium carbonate administration in order to
extend the period of radioiodine EHL and to increase,
in this way, the absorbed dose of radioiodine [4, 11, 12].
Taking into consideration the above-mentioned facts
and observations, the goal of the study was to evaluate
the outcome of131I treatment in hyperthyroid patients,
when combined with parallel administration of thiama-
zole or lithium carbonate or prednisone.
The effect of the initial hormonal status on the final
therapeutic effect also became a subject of the study
evaluation in 131I-treated patients, in whom combined,
parallel administration of lithium carbonate or predni-
sone was applied.
Material and methods
The reported retrospective study involved 200 patients
with hyperthyroidism, treated with radioactive iodine
(131I). In the evaluated population of 200 patients, the
following five (5) groups were identified:
— Group I — patients with TNG or GD, receiving thia-
mazole in a dose of 15–20 mg daily. Thiamazole was
not administered to those patients on the day of ra-
dioiodine administration;
— Group II — patients with TNG or GD and demon-
strating short EHL, administered lithium carbonate
in a daily dose of 750 mg for 3 days before the therapy
with 131I, to be further continued for the subsequent
7 days after radioiodine therapy completion;
— Group III — patients with TNG or GD, treated exc-
lusively with radioiodine (a control group for the
patients in Group I and Group II);
— Group IV — patients with GD and coexisting GO,
receiving prednisone in a dose of 1 mg per kg of
body weight during the peritherapeutic period (first
— continued in full dose for 4 weeks, starting the
administration a day before 131I application, to be
gradually withdrawn with 5 mg/week reduction
rate);
— Group V — patients with GD without GO, treated
exclusively with radioiodine (a control group for the
patients in Group IV).
In the studied population of patients, the hormonal
status was analyzed based on serum concentrations of
free triiodothyronine (fT3), free thyroxine (fT4), fT4) and
thyrotropin (TSH) before the application of 131I.
The following two subgroups of patients were di-
stinguished:
— patients in hormonal and clinical euthyroidism, fol-
lowing pretreatment with thiamazole,
— patients with TSH suppression (< 0.3 mIU/ml) and
with increased levels of fT3 and/or fT4, as well as with
slight symptoms of hyperthyroidism.
The age of the 200 patients in the study varied wi-
thin the range 19 to 81 years, while the mean age for
the entire population was 52.1 ± 13.1 years (mean age ±
± standard deviation), including 171 women – their
mean age being 51.7 ± 12.8 years and 29 men — their
— the mean age being — 54.8 ± 15.1 years.
All the patients were ultrasonographically examined
in order to evaluate thyroid volume. Scintigraphic exami-
nation of the thyroid gland was performed in all the pa-
tients, together with radioiodine uptake (RAIU) capacity
after 24, 48, and 72 hours from administration of a diagno-
stic capsule with 131I, using a set with a scintillating probe.
Wnioski: Wyniki pracy — będąc potwierdzeniem korzystnego wpływu steroidów i niekorzystnego wpływu leków przeciwtarczyco-
wych na skuteczność 131I u pacjentów z nadczynnością tarczycy — wskazują na konieczność dokładnej analizy leków przyjmowanych
przez pacjentów podczas kwalifikacji do terapii radiojodem. Początkowe stężenie TSH nie ma wpływu na skuteczność leczenia radiojo-
dem, w przypadku kiedy dawki pochłonięte są zbliżone do dawek ablacyjnych. (Endokrynol Pol 2010; 61 (1): 56–61)
Słowa kluczowe: nadczynność tarczycy, jod radioaktywny, leki przeciwtarczycowe, węglan litu, kortykosteroidy
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With subsequent measurements of thyroid RAIU,
EHL of radioiodine was determined and expressed in
days.
Radioactive iodine (131I) was administered in a ho-
spital environment in rooms specially adapted and in-
tended for the procedure. The patients were admini-
stered 131I in fasting state, orally, as Na 131I (natrium io-
dide). Each patient obtained written information on the
principles of the treatment and regulations of radiolo-
gical protection, and provided written informed con-
sent for the treatment protocol. The irradiation activi-
ties applied to patients were within the limits of the
doses used in hyperthyroidism therapy. The patients in
Groups I, II, and III received therapeutic activity of 131I,
calculated on the basis of assumed absorbed dose in the
range 150 to 200 Gy, while the patients in Groups IV and
V received 131I therapeutic activity calculated on the ba-
sis of assumed absorbed dose in the range 250 to 350 Gy.
The applied therapeutic activities of 131I in the exa-
mined group of patients were calculated based on the
formula proposed by Marinelli et al. [13].
The effects of radioiodine therapy were evaluated
after six months by observation of the clinical status of
the patients and by laboratory measurements of TSH
and thyroid hormone concentrations.
The results of 131I treatment were assigned to two
subgroups in each of the study groups, according to
the following criteria:
— effective therapy — obtaining the status of euthyro-
idism or hypothyroidism,
—  ineffective therapy — persistent hyperthyroidism.
Methods of selection of homogenous groups
of patients with regard to absorbed dose
and statistical analysis
It appears from the analyses performed by a number of
authors that the parameter demonstrating the highest
influence on the efficacy of 131I therapy is the absorbed
dose [14, 15], indicating that the higher the absorbed
dose, the better the outcome of the therapy with 131I [5, 14].
Therefore, among the patients with hyperthyroidism,
treated with radioactive iodine and submitted to retro-
spective analysis, an attempt was made to select gro-
ups of patients that would be homogenous with regard
to the absorbed dose (150–200 Gy — Groups I, II, and
III and 250–350 Gy — Groups IV and V).
Since it was not possible to group patients with exac-
tly the same values of absorbed dose, Pearson’s point-
biserial statistics was applied to particular groups in
order to answer the question as to what extent the dif-
ferences in applied absorbed doses affected the overall
outcome of radioiodine therapy. Within each study gro-
up (I-V), the absorbed doses were compared between
patients in whom the therapy was effective (euthyro-
idism or hypothyroidism) and ineffective (persistent
hyperthyroidism). No statistically significant differences
were found in those comparisons: Group I — p = 0.66,
Group II — p = 0.21, Group III — p = 0.45, Group IV
— p = 0.30, and Group V — p = 0.37. Such results suggest
homogeneity of the examined groups as to the absorbed
doses received during 131I treatment. The above approach
enabled an attempt to be made to evaluate the effects of
administered drugs on the outcome of 131I therapy.
We applied c2 test for the evaluation of the relation-
ship between the employed protocol of treatment and
the effectiveness of 131I therapy. Two-tailed Fisher’s exact
test was used for the assessment of influence of initial
hormonal status on the outcome of 131I therapy, i.e. de-
tection of possible significant differences between thera-
py success and failure. For the comparison of medians of
absorbed doses in control groups, U Mann-Whitney’s test
was applied. The Statistica 6.0 software package was
employed for calculations. A level of significance p £ 0.05
was regarded as statistically significant.
Results
The number and percentage of patients with effective
radioiodine therapy in particular groups are given in
Table I.
Table I. Effectiveness of radioiodine therapy in particular examined groups of patients
Tabela I. Skuteczność terapii radiojodem w poszczególnych badanych grupach pacjentów
Examined groups Effective therapy Ineffective therapy
Euthyroidism (Eu) Hypothyroidism (HypT) Eu + HypT
Group I 14 subjects 35% 8 subjects 20% 22 subjects 55% 18 subjects 45%
Group II 11 subjects  27.5% 18 subjects 45% 29 subjects 72.5% 11 subjects 27.5%
Group III 24 subjects 60% 7 subjects 17.5% 31 subjects 77.5% 9 subjects 22.5%
Group IV 12 subjects 30% 23 subjects 57.5% 35 subjects 87.5% 5 subjects 12.5%
Group V 11 subjects 27.5% 17 subjects 42.5% 28 subjects 70% 12 subjects 30%
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Comparison of the efficacies of radioiodine therapy
in particular groups are given in Tables II, III, and IV.
The obtained values of c2 statistics indicate that thia-
mazole administration had unfavourable effects on the
outcome of 131I therapy (Table II).
Administration of lithium carbonate had no effect
on the outcome of 131I therapy (Table III). However,
prednisone administration had advantageous effects on
the outcome of 131I therapy (Table IV).
Evaluation of the influence of initial hormonal and
clinical status on the outcome of 131I therapy was con-
ducted only in the groups of patients receiving lithium
carbonate or prednisone. The analysis was not perfor-
med in the patients receiving thiamazole (Group I), since
all the patients in that group were initially hyperthyro-
id. For the analysis in question, at the beginning of stu-
dy the following two subgroups were identified in the
prednisone group and lithium carbonate group: 1) pa-
tients with suppressed TSH concentrations and eleva-
ted concentrations of thyroid hormones, and 2) patients
with normal TSH concentrations. Next, the patients
were assigned to one of the following two subgroups
according to the final effect of therapy: 1) effective the-
rapy (euthyroidism or hypothyroidism) or 2) ineffecti-
ve therapy (hyperthyroidism).
The obtained results of the above-mentioned ana-
lysis demonstrated that in Group II, in patients with
initially normal TSH concentrations, the effectiveness
of therapy was 100.0% (11/11 patients), while in patients
with suppressed TSH, the therapy was effective in 62.0%
(18/29 patients). Similarly, in Group III, in patients with
normal TSH concentrations at the beginning of the stu-
dy, the efficacy of therapy was 91.0% (21/23 patients)
whereas in patients with suppressed TSH, the therapy
effectiveness amounted to 59.0% (10/17 patients). It can
be assumed that the normal TSH values, obtained prior
to the basic treatment (131I), exerted a beneficial effect
on the efficacy of radioiodine therapy (p = 0.02, in both
Groups II and III, two-tailed Fisher’s exact test).
A similar analysis of the relationship between the
initial level of TSH and the therapy effectiveness was
performed for Groups IV and V, with the following re-
sults: in Group IV, in patients with normal TSH con-
centrations, the therapy was effective in 86.0% (12/14
patients), while in patients with suppressed TSH con-
centrations the therapy was effective in 88.5% (23/26
patients). In Group V, in patients with normal values of
TSH concentrations at the beginning of study, the the-
rapy was effective in 85.0% (11/13 patients), while in
patients with suppressed TSH concentrations, the the-
rapy was effective in 63.0% (17/27 patients).
Summing up, in Group IV a similar effectiveness of
therapy was obtained regardless of the initial TSH con-
centration, while in Group V a slightly higher efficacy
was found in patients with normal values of TSH con-
centrations at the beginning of treatment. However, in
both instances, the results were statistically insignificant
(two-tailed Fisher’s exact test, Group IV — p = 0.99,
Group V — p = 0.2). Thus, it may be concluded that
both in the group of patients, receiving 131I together with
prednisone in the peritherapeutic period (Group IV)
Table II. Comparison of 131I therapy effectiveness in Groups I
and III (c2 = 4.53, p = 0.03)
Tabela II. Porównanie skuteczności terapii radiojodem
w grupach I i III (c2 = 4,53, p = 0,03)
Therapy The number of patients
effectiveness in particular groups
Group I Group III Total
Effective therapy 22 (27.50%) 31 (38.75%) 53 (66.25%)
Ineffective therapy 18 (22.50%) 9 (11.25%) 27 (33.75%)
Total 40 (50.00%) 40 (50.00%) 80 (100.00%)
Table III. Comparison of131I therapy effectiveness in Groups II
and III (c2 = 0.27, p = 0.61)
Tabela III. Porównanie skuteczności terapii radiojodem
w grupach II i III  (c2 = 0,27, p = 0,61)
Therapy The number of patients
effectiveness  in particular groups
Group II Group III Total
Effective therapy 29 (36.25%) 31 (38.75%) 60 (75.00%)
Ineffective therapy 11 (13.75%) 9 (11.25%) 20 (25.00%)
Total 40 (50.00%) 40 (50.00%) 80 (100.00%)
Table IV. Comparison of 131I therapy effectiveness in Groups IV
and V (c2 = 3.66, p = 0.05)
Tabela IV. Porównanie skuteczności terapii radiojodem
w grupach IV i V (c2 = 3,66, p = 0,05)
Therapy The number of patients
effectiveness in particular groups
Group IV Group V Total
Effective therapy 35 (43.75%) 28 (35.00%) 63 (78.75%)
Ineffective therapy 5 (6.25%) 12 (15.00%) 17 (21.25%)
Total 40 (50.00%) 40 (50.00%) 80 (100.00%)
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and in the controls (Group V), the initial hormonal sta-
tus had no effect on the final outcome of 131I therapy.
Discussion
The treatment of hyperthyroidism with radioactive io-
dine is a very effective method; however, remission is
not obtained in all patients after a single dose of radio-
iodine. For many years, therapeutic methods have been
searched for to improve their efficacy. There are some
premises that simultaneous administration of radioac-
tive iodine and of certain thyroid function affecting
drugs could improve the overall outcome of treatment.
Studies on the use of antithyroid drugs combined with
radioiodine have been conducted for a number of years,
although the effects of these drugs on the effect of ra-
dioiodine therapy is still a subject of dispute. We have
confirmed, in the present study, that thiamazole used
in combination with 131I reduces the therapeutic effecti-
veness of this isotope. Similar conclusions have been
drawn by other authors [16–18], who explain the obse-
rvation by the fact that antithyroid drugs decrease io-
dine uptake by the thyroid gland. In addition, by dete-
riorating the intrathyroid iodine resources, they contri-
bute to the so-called quick turnover of iodine in the thy-
roid gland. In consequence, the EHL of radioiodine is
shorter and the overall effectiveness of treatment is lo-
wer. Some authors [16, 19] underline the radioprotecti-
ve effects of antithyroid drugs, which result in a lower
biological effect with comparable dose absorbed by the
thyroid gland.
However, some other authors did not see any influ-
ence of antithyroid drugs on the outcome of radioiodi-
ne therapy in their studies [20, 21].
Radioactive iodine should not be used in patients
with high concentrations of free thyroid hormone (fT3
and fT4) because of the risk of hyperthyroidism enhan-
cement. However, sometimes it is difficult to obtain
normal thyrometabolic status before radioiodine thera-
py; there are also patients in whom even a short-term
withdrawal of antithyroid drug administration enhan-
ces the symptoms of hyperthyroidism. Therefore, re-
garding those patients, administration of antithyroid
drugs is recommended during the peritherapeutic pe-
riod of 131I therapy.
In the above-mentioned literature items, only Sabri
et al. [14] evaluated the correlation between the effecti-
veness of therapy with 131I in hyperthyroid patients who
were given thyrostatic drugs and the value of the ab-
sorbed dose of irradiation. In their study, similarly to
our present contribution, Pearson’s statistics was ap-
plied — point biserial statistics.
Short EHL of iodine in the thyroid gland is an es-
sential problem before radioiodine administration plan-
ning because it results in shorter exposition time of the
thyroid tissue to irradiation, thus deteriorating the fi-
nal outcome of 131I therapy. However, it seems that com-
plimentary administration of lithium carbonate may
improve the results of 131I in hyperthyroidism.
Bogazzi et al. [12] studied two groups of hyperthy-
roid patients. The patients of one of these groups were
treated with radioiodine only, while the patients in the
second group additionally received lithium carbonate
in a dose of 900 mg/day for six consecutive days star-
ting on the day of 131I therapy onset. In their study, in
the group of patients who were receiving lithium car-
bonate, higher efficacy of radioiodine therapy was ob-
served; earlier, euthyroidism was obtained in those pa-
tients with more pronounce reduction of goitre size. The
authors explain their results by the antithyroid drug
properties of lithium carbonate and extended retention
of the radionuclide in the thyroid [12]. Similar conclu-
sions were obtained by Dunkelmann et al. [4]. Contra-
ry to general expectations, the authors of that study did
not demonstrate any significant effect of lithium carbo-
nate on the outcome of radioiodine therapy in the stu-
died group of patients [4]. There are also other reports
contradicting the advantageous effects of lithium car-
bonate on the overall outcome of 131I therapy [22, 23]. In
our present study we have failed to demonstrate any
beneficial effect of lithium carbonate for 131I therapeutic
outcome.
Corticosteroids are not commonly used as compli-
mentary treatment before 131I administration; first of all,
they play a key role in treating thyroid orbitopathy.
According to many authors [5, 10, 24], corticosteroid
administration should be considered in cases of radio-
iodine treatment of hyperthyroidism with accompany-
ing thyroid orbitopathy. They are believed to prevent
the symptoms of orbitopathy from becoming more acu-
te. Therefore, following the recommendations, as found
in literature, the studied patients in Group IV — i.e.
patients with hyperthyroidism in the course of GD with
accompanying GO, received corticosteroids in the “pe-
ritherapeutic” period of 131I administration in a dose of
1 mg per kg of body weight/day. All the patients with
hyperthyroidism in the course of GD (Group IV and
Group V) received ablative doses of radioiodine.
However, the goal of the reported study was not
the evaluation of corticosteroid therapy on the course
of GO, but to find out whether their administration had
any effect on radioiodine therapy of hyperthyroidism.
The issue of corticosteroid application and of their ef-
fect on the outcome of radioiodine treatment in hyper-
thyroid patients has been approached but in just a few
reports.
In our present study, prednisone, applied in hyper-
thyroid patients in the course of GD and accompany-
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ing GO (Group IV), significantly increased the efficacy
of 131I therapy.
Jude et al. [25] described a case of two patients in
whom it was difficult to compensate thyrometabolic
state by means of applied antithyroid drugs, while only
prednisone administration brought control over hyper-
thyroidism and enabled effective therapy with radioio-
dine. The authors suggest that corticosteroids may be
used to bring about balanced thyroid functionality in
combination with antithyroid drugs. However, Barta-
lena et al. [10] studied the effects of corticosteroids on
the effects of radioiodine treatment of hyperthyroidism,
finding that in both a group of patients receiving corti-
costeroids and in a group with no corticosteroid admi-
nistration, the effectiveness of the basic (131I) therapy
was almost the same. Similar conclusions were obtained
by Jensen et al. [26]. Kloza et al. [27] demonstrated in
their study a significant correlation between hyperthy-
roidism recurrence and treatment with corticosteroids
at the time of 131I administration. The authors of the stu-
dy reported that the use of corticosteroids at the time
of radioiodine treatment was identified as an unequ-
ivocally bad prognostic factor for the therapy with ra-
dioactive iodine.
In our present investigation, the evaluation also en-
compassed the effect of the initial hormonal status on
the final effect of 131I therapy in Groups II, III, IV, and V.
It appears from the performed evaluation that, taking
into account Groups II and III, normal TSH values exert
beneficial effects on the efficacy of radioiodine thera-
py, but in Groups IV and V the initial hormonal status
had no effect on the efficacy of 131I therapy.
It is worth some deliberation why, in the two gro-
ups of patients treated with radioiodine only (Groups
III and V – the— control groups), the obtained results
were not the same. In Group III the obtained status of
metabolic euthyroidism had advantageous effects on
the final outcome of 131I therapy, while in Group V no
such relationship was found. The divergence of the two
results may have resulted from different absorbed do-
ses applied in either group. The absorbed dose in Gro-
up III was 150–200 Gy, while the doses applied in Gro-
up V amounted to 250–350 Gy, the latter already being
ablative doses. The median values of absorbed doses in
Groups III and V were compared by means of U Mann-
Whitney’s test, revealing that they did not differ from
each other at the level of statistical significance. Thus, it
seems that the factors considered by many authors to
influence the efficacy of therapy with radioactive iodi-
ne may be less important in cases when the applied the-
rapeutic activities of 131I are calculated on the basis of
ablative absorbed doses.
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